title: Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children.
abstract: OBJECTIVE
  We evaluated piperacillin-tazobactam in association with netilmicin (TN) in the early empirical treatment of neutropenic children, as data are limited in number.
  
  
  METHODS
  In 1996, an observational study was initiated to assess the efficacy and safety of this association, with a glycopeptide (TNG) if needed. The impact on the bacterial ecology of our unit was also observed. Children were treated for hematological malignancy or solid tumor between September 1996 and December 1998 and presented a febrile neutropenia.
  
  
  RESULTS
  There were 148 evaluable febrile neutropenic episodes in 104 patients. Median age was 7 years, 55% of the episodes were fever of unknown origin, 22% were clinically documented and 23% microbiologically documented (27 bacteriemia). A glycopeptide was added in 67 episodes. The initial unmodified treatment was successful in 114 episodes (77%): 75/81 episodes in the TN group and 39/67 in the TNG group. For successful episodes, median treatment duration was 6 days. There were 22 febrile recurrences. These patients, as well as initial failures, always responded to a second-line treatment. One child was considered a failure because he developed a skin rash probably due to piperacillin-tazobactam and required another beta-lactamase.
  
  
  CONCLUSIONS
  This study suggests that piperacillin-tazobactam in association with netilmicin presents a satisfactory efficacy and a good tolerance as empirical therapy for febrile neutropenic children. It allowed us to maintain the bacterial ecology of our unit.
authors.affiliation: Department of Pediatric Haematology and Oncology, Hôpital Armand Trousseau, 26 avenue du Dr., Arnold Netter, 75571 Paris Cedex 12, France.
authors.forename: N
authors.initials: N
authors.lastname: Le Guyader
authors.forename: A
authors.initials: A
authors.lastname: Auvrignon
authors.forename: H
authors.initials: H
authors.lastname: Vu-Thien
authors.forename: E
authors.initials: E
authors.lastname: Portier
authors.forename: M D
authors.initials: MD
authors.lastname: Tabone
authors.forename: G
authors.initials: G
authors.lastname: Leverger
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000139:chemically induced* / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009428:Netilmicin / Q000008:administration & dosage / Q000627:therapeutic use*; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy*; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010878:Piperacillin; D012008:Recurrence; D000078142:Tazobactam; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009428:Netilmicin; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin